Background: Rotavirus is a common infectious cause of childhood hospitalisation in Hong Kong. Rotavirus vaccines have been used in the private sector since licensure in 2006 but have not been incorporated in the government's universal Childhood Immunisation Programme. This study aimed to evaluate rotavirus vaccine effectiveness against hospitalisation. Methods: This case-control study was conducted in the 2014/2015 rotavirus season in six public hospitals. Hospitalised acute gastroenteritis patients meeting inclusion criteria were recruited and copies of their immunisation records were collected. Case-patients were defined as enrolled subjects with stool specimens obtained in the first 48 h of hospitalisation that tested positive for rotavirus, whereas control-patients were those with stool specimens obtained in the first 48 h of hospitalisation testing negative for rotavirus. Vaccine effectiveness for administration of at least one dose of either Rotarix Ò (GlaxoSmithKline Biologicals) or RotaTeq Ò (Merck Research Laboratories) was calculated as 1 minus the odds ratio for rotavirus vaccination history for case-patients versus control-patients. Results: Among the 525 eligible subjects recruited, immunisation records were seen in 404 (77%) subjects. 31% (162/525 and 126/404) tested positive for rotavirus. In the 404 subjects assessed for vaccine effectiveness, 2.4% and 24% received at least 1 dose of either rotavirus vaccine in case-and control-patients respectively. The unmatched vaccine effectiveness against hospitalisation for administration of at least one dose of either rotavirus vaccines was 92% (95% confidence interval [CI]: 75%, 98%). The matched analyses by age only and both age and admission date showed 96% (95% CI: 72%, 100%) and 89% (95% CI: 51%, 97%) protection against rotavirus hospitalisation respectively. Conclusions: Rotavirus vaccine is highly effective in preventing hospitalisation from rotavirus disease in young Hong Kong children.
schedule usually at 2 and 4 months of age. RotaTeq Ò (RV5, Merck
Research Laboratories) is a bovine-human reassortant pentavalent rotavirus vaccine given with a three-dose schedule usually at 2, 4 and 6 months of age. In 2006, these vaccines were reported to be safe and highly efficacious in the Americas and Europe [4, 5] , and subsequently were shown to have about 96% efficacy against severe acute rotavirus gastroenteritis through 2 and 3 years of age in Hong Kong, Singapore and Taiwan [6] [7] [8] . In 2013, the World Health Organization re-confirmed its 2009 recommendation that rotavirus vaccines be included in all National Immunisation Programs (NIP) [9] . An economic evaluation from the Hong Kong government's perspective showed that inclusion of the vaccine in the universal Childhood Immunisation Programme (CIP) would be likely cost-saving if the vaccine cost per course was less than USD 40-92 assuming a vaccine efficacy of 96% for preventing hospitalisations and 89.5% for preventing outpatient visits [10] . This analysis did not include societal or wider economic benefits such as herd protection [11] , reduction of nosocomial infections [12] and reduction of seizures [13] . Since 2012 the Hong Kong CIP offers vaccines to all children at no cost to the families that protect against 11 infectious diseases (Bacillus Calmette-Guérin, hepatitis B, diphtheria, acellular pertussis, tetanus, inactivated polio, 13-valent conjugate pneumococcus, measles, mumps, rubella and varicella). Although both rotavirus vaccines have been licensed in Hong Kong since 2006, they have not been included in the CIP and have only been available in the private sector. This non-universal use of rotavirus vaccine has allowed us to evaluate rotavirus vaccine effectiveness in Hong Kong.
Methodology

Subjects
During the 2014/2015 rotavirus season, we conducted a casecontrol study to assess rotavirus vaccine effectiveness in acute gastroenteritis (AGE) patients admitted to public hospitals in Hong Kong. During this period Hong Kong's Hospital Authority managed 12 government funded public hospitals with general paediatric services. These 12 hospitals were officially grouped into seven clusters. This study was carried out in six public hospitals located from six clusters: Kwong Wah Hospital, Prince of Wales Hospital, Queen Elizabeth Hospital, Queen Mary Hospital, Tuen Mun Hospital and United Christian Hospital. An estimated 71% of all inpatient paediatric care in Hong Kong is provided by these public hospitals [14] . Although families from higher socioeconomic backgrounds are more likely to use the private sector, public hospitals provide care for all Hong Kong residents from all socioeconomic backgrounds.
AGE was defined as the occurrence of two or more episodes of vomiting and/or three or more episodes of diarrhoea (stools of a less formed character than usual) within a 24-h period. Families of children meeting the inclusion criteria were invited to participate in the study. Inclusion criteria for selection of subjects included: (1) admitted to one of the study hospitals for treatment of AGE during the study period; (2) aged from 30 days to below 5 years; (3) onset of diarrhoea or vomiting started less than or equal to 14 days before admission; (4) normally receive vaccination and/or medical care in Hong Kong; and (5) written informed consent obtained from parents or guardians. Patients with parents or guardians unable to speak Chinese (Cantonese or Mandarin) or English were excluded. Research staff identified the potential AGE patients by looking up the admission records of hospitalised children with AGE symptoms. However, since these records may not reflect the real diagnoses at recruitment, some recruited patients were subsequently shown not to have a diagnosis of AGE. Discharge summaries or case records were reviewed independently by two of the authors and non-AGE patients were excluded from the analysis. Subjects without stool specimens known to be collected and tested for rotavirus within the first 48 h of hospitalisation and subjects without copies of immunisation records were excluded from the final analyses.
Rotavirus testing was performed on routinely collected stool specimens from diarrhoea patients at five of the six study hospitals (except Kwong Wah Hospital). During the study period, stool specimens were collected from diarrhoea patients at Kwong Wah Hospital and transported on ice for rotavirus testing with enzyme immunoassay (EIA) at the Prince of Wales Hospital laboratory. Specimens from four of the study hospitals were tested for rotavirus by EIA and by reverse-transcriptase-polymerase chain reaction (RT-PCR) at the remaining two sites (Appendix). Case-patients were defined as AGE recruited subjects with stool specimens obtained during the first 48 h of hospitalisation that tested positive for rotavirus, whereas the control-patients were AGE recruited subjects with stool specimens obtained within the first 48 h of hospitalisation testing negative for rotavirus (i.e. test-negative controls). Analyses were done using three groups of controls: (1) matched with case-patients by date of birth (±30 days) and date of admission (±30 days); (2) matched by date of birth only; and (3) unmatched controls. The matched analyses allowed for up to 5 control-patients to be matched to each case-patient without replacement.
Data collection
Parents or guardians of recruited patients were interviewed at the study hospitals with a standardised questionnaire [15] modified for local use. Demographic information, birth and medical history were collected. Admission details, disease severity, final diagnoses and laboratory results were obtained from patients' medical records. Copies of subjects' immunisation records were obtained from their parents or guardians after interviews. If the immunisation records were not available during the hospital admission, verbal reports of vaccination history were collected and copies of immunisation records were requested to be sent by text message, e-mail, fax or post.
Statistical analyses
Characteristics of case-patients and control-patients were compared using chi-square tests and Wilcoxon rank-sum tests. Diarrhoea severity was examined by using the Vesikari score [16] and other markers such as length of hospital stay and the use of intravenous fluids. A dose of vaccine was considered relevant if it was administered at least 14 days before admission. Patients were regarded as fully vaccinated if they had received 2 doses of RV1 or 3 doses of RV5, whereas patients were regarded as partially vaccinated if they had received 1 dose of RV1 or 1-2 doses of RV5. For the unmatched analysis, we used unconditional logistic regression, adjusting for age on admission and month of admission, to obtain the adjusted odds ratios (ORs) for rotavirus vaccination rate (at least one dose and full series versus unvaccinated) among casepatients compared with control-patients. Conditional logistic regressions were used for matched analyses. We investigated rotavirus vaccine effectiveness using each of the control groups. Vaccine effectiveness was calculated as (1 -OR) Â 100, where the ORs were those obtained from the unconditional and conditional logistic regressions. All analyses were performed using statistical software R version 3.2.2 and SAS version 9.3 (SAS Institute, Cary, NC). A two-tailed p-value of <0.05 was considered statistically significant. 
Ethics approvals
Results
From 31 October 2014 to 23 April 2015 (covering the 2014/2015 rotavirus season in Hong Kong), there were a total of 2189 potential AGE patients listed in admission records, of which 573 (26%) were not approached by research staff (Fig. 1) . Among the 1616 subjects approached, 575 (36%) did not meet the initial inclusion criteria screening, 129 (8%) refused to participate and 45 (3%) were discharged before consent could be obtained. Among the 867 subjects enrolled in the study, 168 (19%) were subsequently found not to meet the inclusion criteria and 174 (20%) Refused to participate n = 129
Excluded from analysis n = 342
1. Diarrhoea and/or vomiting was not the main reason for admission (n = 145) 2. Unknown start day of illness (n = 4) 3. AGE definition not known to be met (n = 19) 4. Stool sample not obtained during hospitalisation (n = 148) 5. Stool sample not known to be obtained in the first 48 hours of hospitalisation (n = 16) 6. Rotavirus testing not taken (n = 10) Discharged before consent obtained n = 45
Total potential acute gastroenteritis (AGE) patients listed in admission records n = 2189
Patients not approached by research staff n = 573
Without copies of immunisation records obtained n = 121 did not have stool specimens known to be collected and tested for rotavirus within the first 48 h of hospitalisation. Among the 525 eligible subjects, 404 (77%) provided copies of immunisation records and were included in the analyses assessing vaccine effectiveness.
Patients without a rotavirus test result were not significantly different from those who did have stool specimens collected and tested in terms of gender, number of rooms for sleeping and number of other children aged under 10 years in the same household, breastfeeding history, treatments given before admission (use of antibiotics and oral rehydration solution), intravenous fluids during hospital stay and rotavirus vaccination status. However, these patients were older and more likely to have vomiting only during the illness, had lower maximal body temperature and a shorter length of hospital stay, and to have more highly educated parents (Table 1 ). This reflected that stool specimens were not collected for those recruited patients with vomiting only at admission and who did not develop diarrhoea during the hospital admission. Although there was no difference in rotavirus vaccination status between these two groups, more guardians of patients with stool specimens collected and tested were aware of rotavirus vaccine before their child reached the age of six months (p-value = 0.04).
Among the 404 subjects with immunisation records seen that were included in the analyses for vaccine effectiveness, stool specimens of 126 (31%) subjects tested positive for rotavirus and 278 (69%) tested negative. 32% of rotavirus-positive patients were admitted in January 2015, the peak of the 2014/15 rotavirus season. Compared to the rotavirus-negative patients, the rotaviruspositive patients did not differ significantly with regard to gender, number of rooms for sleeping and number of other children aged under 10 years in the same household, treatments given before admission (use of antibiotics and oral rehydration solution) and highest body temperature during the illness (Table 2) . However, when compared with rotavirus-negative patients, the rotaviruspositive patients were significantly older, had more severe illness (longer length of hospital stay, higher Vesikari score and more likely to receive intravenous fluids), were less likely to have ever been breastfed or exclusively breastfed, to have parents with high Table 1 Comparison of demographic characteristics, symptoms, severity, treatments and vaccination status between patients with and without stool specimens tested for rotavirus. educational level, and to have guardians who were aware of rotavirus vaccine before 6 months old.
2.4% of the 126 rotavirus-positive patients were fully vaccinated with rotavirus vaccines (1 subject received RV1 and 2 subjects received RV5) and none were partially vaccinated. For rotavirusnegative patients, 21% and 3.2% received full series (46 subjects received RV1 and 12 subjects received RV5) and partial series (5 subjects received RV1 and 4 subjects received RV5) of rotavirus vaccines respectively. Since the numbers of patients vaccinated with specific vaccine types and partial series were insufficient to provide meaningful subgroup analyses, we calculated vaccine effectiveness by combining the numbers of patients vaccinated with either brand and for either partial or full series of rotavirus vaccination.
For the unmatched analyses of the 404 subjects with immunisation records seen, the unadjusted vaccine effectiveness for at least one dose of rotavirus vaccine was 92% (95% confidence interval [CI]: 75%, 98%) ( Table 3 ). The same results for vaccine effectiveness were obtained after adjusting for patients' age, both with and without adjustments for month of admission (92% [95% CI: 75%, 98%]). 288 subjects could be matched by date of birth. 2.1% (2/97) of these age-matched case-patients and 25% (48/191) of agematched control-patients were vaccinated with at least one dose of rotavirus vaccine, giving a vaccine effectiveness of 96% (95% CI: 72%, 100%). 214 subjects could be matched by both date of birth and admission date. 2.5% (2/79) of these age-and admission datematched case-patients and 23% (31/135) of age-and admission date-matched control-patients were vaccinated with at least one dose of rotavirus vaccine, giving a vaccine effectiveness of 89% (95% CI: 51%, 97%). We additionally calculated vaccine effectiveness for full series rotavirus vaccination only, which was similar to the combined full and partial series results (88-96% in matched and unmatched analyses).
Analyses were also done on a restricted group of patients old enough to be fully vaccinated with rotavirus vaccine (above 32 weeks). Similar vaccine effectiveness estimates were obtained to the unrestricted models (data not shown). Vaccine effectiveness of at least one dose of rotavirus vaccine has also been estimated for different age groups below five by unmatched analyses with and without adjustment and matched analyses. The unmatched and unadjusted vaccine effectiveness were 88% (95% CI: 59%, 96%) over Table 2 Comparison of demographic characteristics, symptoms, severity, treatments and vaccination status between rotavirus-positive and rotavirus-negative patients with immunisation records seen (n = 404).
Rotavirus positive
Rotavirus negative P-value (n = 126) (n = 278) the first two years of life, 90% (95% CI: 69%, 97%) over the first three years of life and 92% (95% CI: 74%, 98%) over the first four years of life ( Table 4 ). The small sample size made it impossible to investigate vaccine effectiveness stratified by exclusive breastfeeding history. However, unconditional and unadjusted vaccine effectiveness for at least one dose of rotavirus vaccine in never breastfed and ever breastfed groups were 91% (95% CI: 28%, 99%) and 93% (95% CI: 70%, 98%) respectively.
Discussion
This is the first post-licensure evaluation on rotavirus vaccine effectiveness in Hong Kong. Rotavirus vaccine of at least one dose was highly effective and had 89%-96% ability to prevent hospitalisation from rotavirus disease. Our findings are comparable to a previous local clinical trial showing 92.6% vaccine efficacy of RV1 against rotavirus gastroenteritis requiring hospitalisation until three years of age [8] and a Taiwanese study showing 90% (RV1) and 97% (RV5) vaccine effectiveness post-vaccine introduction [17] . A sample of studies from high income countries (Australia, Belgium, Israel, Spain and the United States) using design similar to ours have shown vaccine effectiveness ranging from 78% to 98% (Table 5) .
In a local hospital-based surveillance study conducted from 2001 to 2003 [1] , 30% of children admitted to hospital with diarrhoea, and stool specimens tested, were positive for rotavirus. In our study, 31% of all gastroenteritis subjects with stool specimens tested were positive for rotavirus. Although this proportion of rotavirus diarrhoea is similar to that seen a decade ago it should be noted that our study covered only the rotavirus season when the proportion of rotavirus AGE would be expected to be higher. Interestingly, a recent local study using hospital discharge data from 1997 to 2011 showed no apparent decline in the incidence of hospitalisation for rotavirus in children under the age of five following the availability of rotavirus vaccines in 2006 [2] . This may have reflected a relatively low uptake of rotavirus vaccines within the private sector in Hong Kong during these earlier post-licensure years. In the present study, 17% of all subjects and 24% of the rotavirus-negative subjects had received rotavirus vaccine through the private sector. As noted above, countries that introduced rotavirus vaccines into their NIPs, such as the United States and Australia, have witnessed dramatic reductions in rotavirus (67-86%) [18] [19] [20] and all-cause AGE (16-46%) [21, 22] admissions. In Hong Kong 9.8% of 824,514 children aged below five years and admitted to the paediatric wards of public hospitals during the period 1 July 1997 to 31 March 2011 had a primary discharge diagnosis code indicating a gastroenteritis-associated disorder [2] . The estimated incidence rate of gastroenteritis (primary discharge diagnosis only) was 3347 per 100,000 person-years. 1.6% of these 824,514 children had either a primary or secondary discharge code of rotavirus, Table 3 Vaccine effectiveness against rotavirus hospitalisation according to different approaches of analyses in 404 eligible subjects with immunisation records seen.
Received at least one dose
Fully vaccinated % (n/Total) VE (95% CI) (%) % (n/Total) VE (95% CI) (%) VE, vaccine effectiveness; CI, confidence interval. # % (n/Total) = proportion of subjects ever received rotavirus vaccine.
equating to an incidence rate of rotavirus of 542 per 100,000 person-years. However after adjusting for likely under-coding and under-testing of rotavirus the incidence rate for hospital admission due to rotavirus was 1093 per 100,000 person-years. Incorporation of rotavirus vaccine into the CIP could significantly reduce the rotavirus hospitalisation rate of Hong Kong children. This study has some limitations. First, there were 573 (26%) potential AGE patients not approached by research staff and 45 (3%) patients approached but discharged before consent could be obtained during the recruitment period. Potential differences between the non-recruited and recruited subjects could affect our estimates of vaccine effectiveness. No information was collected for patients who were not approached but with verbal consent some limited information was collected from guardians who declined to participate. The latter group was not significantly different from the enrolled group with regard to age, gender, parental educational level and verbal report on rotavirus vaccination status but mothers were significantly older. However, maternal age was not found to be a potential factor affecting estimates of vaccine effectiveness. Second, AGE patients without a rotavirus test result were found to be more likely to have vomiting only during the illness and had lower maximal body temperature and a shorter length of hospital stay. This group of patients was more likely to have been vaccinated with rotavirus vaccine. Since they were not included in the analyses, our estimated vaccine effectiveness might have been underestimated. Third, copies of immunisation records were obtained for only 77% of the 525 eligible subjects. This reduced the sample size for analyses of vaccine effectiveness. The proportion of patients with stool tested rotavirus-positive and guardians' verbal report on rotavirus vaccination status were not significantly different between those who provided and who did not provide their immunisation records. However guardians of patients who provided immunisation records were more likely to report that they were aware of rotavirus vaccine before their children were 6 months old. Analyses of vaccine effectiveness were repeated for all 525 eligible subjects using the guardians' verbal report of rotavirus vaccination history and similar estimates of effectiveness were obtained to the models using data of the 404 subjects with immunisation records seen (data not shown). 98% (397/404) of the immunisation records obtained confirmed the guardians' previous verbal report of rotavirus vaccination status. This suggests that recall bias of rotavirus vaccination may be relatively small and that verbal reports of rotavirus vaccination status could be used in studies where obtaining confirmation of vaccination status is difficult. Fourth, since this was a relatively mild season, the number of potential AGE patients was small. The government activated a serious response level (S2) alert because of reports of H7N9 influenza in the vicinity. This required suspension of all research activities on infectious disease wards and hindered recruitment during the period of 26 December 2014 to 15 January 2015 (peak of 2014/2015 rotavirus season) when 132 potentially eligible subjects could not be approached. Consequently, our sample size was reduced resulting in less precise estimates of vaccine effectiveness. Finally, use of RT-PCR to identify rotavirus cases at two of the six study hospitals may have resulted in detection of a low level of rotavirus in the stool that was not causally associated with AGE in these patients and thus underestimated the vaccine effectiveness [23] .
In conclusion, rotavirus vaccine is highly effective in preventing rotavirus AGE hospitalisation. Incorporation of the vaccine into the CIP could significantly reduce hospitalisations of Hong Kong children aged below five years.
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